Lorna Jane, an Australian activewear company, was recently fined AU$5 million after claiming that its new line of active clothing can stop the spread of COVID-19. The firm said that its clothing could eliminate the virus, thus preventing its spread.
According to BBC News, Lorna Jane released advertisements that say it is using a groundbreaking technology called LJ Shield for its clothing line. It was claimed that this could stop the "transfer of all pathogens."
What the court says on Lorna Jane’s claims
Based on the report, a judge said in a ruling that the company’s claim about LJ Shield is "exploitative, predatory and potentially dangerous." The legal action against Lorna Jane was filed by the Australian Competition & Consumer Commission (ACCC) after the firm started selling its clothing in July amid the COVID-19 pandemic.
The verdict was said to have been released by the federal court on Friday, July 23. The judge said that based on investigations, Lorna Jane has been telling the consumers it has a “reasonable scientific or technological basis" for its claims about its clothing with the LJ Shield.
However, the judge said there was actually no scientific basis for such a claim. For this false and misleading representation to the public, the court slapped the company with a hefty fine.
"This was dreadful conduct as it involved making serious claims regarding public health when there was no basis for them," chairman of the ACCC, Rod Sims, said. "The whole marketing campaign was based upon consumers' desire for greater protection against the global pandemic."
Lorna Jane accepts the judge’s decision
The company was said to have accepted the verdict but explained, it was also misled by its supplier. Lorna Jane claimed its supplier sold them a product that did not deliver what it claimed to be, and they are referring to what they called the LJ Shield technology that is supposed to be anti-viral and anti-bacterial.
Meanwhile, it was learned that this is not the first time that Lorna Jane was fined. As per The Guardian, just in July 2020, the company was fined $40,000 for its failure to seek proper approval for ads from the Therapeutic Goods Administration. As for this new issue, the company issued an apology for its customers while continuing to blame its supplier for the issue.


Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Yen Slides as Japan Election Boosts Fiscal Stimulus Expectations
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



